<DOC>
	<DOCNO>NCT00928668</DOCNO>
	<brief_summary>The primary objective study ass efficacy ( bronchoprotection ) safety single dos BI 1744 CL inhalation solution ( 2 , 5 , 10 20 mcg ) deliver via Respimat® inhaler , patient intermittent asthma .</brief_summary>
	<brief_title>Efficacy ( Bronchoprotection ) Safety Orally Inhaled BI 1744 CL Patients With Intermittent Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Olodaterol</mesh_term>
	<criteria>Inclusion criterion 1 . Diagnosis intermittent asthma accord Global Initiative Asthma criteria 2 . Nonsmokers exsmokers smoke least 1 year smoke history le 5 packyears 3 . Forced Expiratory Volume 1second great equal 80 % predict normal ( Visit 1 ) . 4 . Bronchial hyperresponsiveness inhale methacholine provocative concentration methacholine cause 20 % fall Forced Expiratory Volume one second le equal 8 mg/mL ( Visit 1 ) . 5 . Be able perform technically acceptable pulmonary function test 6 . Be able inhale medication competent manner Respimat® inhaler 7 . Must sign date inform consent consistent International Conference HarmonisationGood Clinical Practice guideline prior participation trial , include medication washout restriction . Exclusion criteria 1 . Patients significant disease asthma 2 . Patients seasonal asthma allergy whose participation trial occur season allergic . 3 . Patients clinically relevant abnormal baseline haematology , blood chemistry , urinalysis ; patient serum glutamic oxaloacetic transaminase &gt; 80 IU/L , serum glutamic pyruvic transaminase &gt; 80 IU/L , bilirubin &gt; 2.0 mg/dL creatinine &gt; 2.0 mg/dL exclude regardless clinical condition 4 . Patients follow condition : diagnosis hyperthyrosis paroxysmal tachycardia ( &gt; 100 beat per minute ) , mark baseline prolongation QT/QTc interval , history additional risk factor Torsade de Pointes , history myocardial infarction , diagnosis clinically relevant cardiac arrhythmia , history cor pulmonale , know active tuberculosis , malignancy patient undergone resection , radiation therapy chemotherapy within last five year ( patient treat basal cell carcinoma allow ) , history lifethreatening pulmonary obstruction , history cystic fibrosis , clinically evident bronchiectasis , history significant alcohol drug abuse . 5 . Patients undergone thoracotomy pulmonary resection 6 . Patients treat follow concomitant medication : medication prolong QT/QTc interval , oral betaadrenergics , betablockers monoamine oxidase inhibitor tricyclic antidepressant . 7 . Patients treat respiratory medication ( exclude shortacting betaagonists ) control asthma symptom within 3 month Screening Visit ( Visit 1 ) . 8 . Patients take investigational drug within one month six half life ( whichever great ) prior Screening Visit ( Visit 1 ) . 9 . Pregnant nursing woman , woman childbearing potential use highly effective method birth control .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>